These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 35989353)

  • 1. Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells.
    Khozooei S; Lettau K; Barletta F; Jost T; Rebholz S; Veerappan S; Franz-Wachtel M; Macek B; Iliakis G; Distel LV; Zips D; Toulany M
    J Exp Clin Cancer Res; 2022 Aug; 41(1):256. PubMed ID: 35989353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells.
    Lettau K; Zips D; Toulany M
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):567-580. PubMed ID: 32931865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fisetin overcomes non-targetability of mutated KRAS induced YB-1 signaling in colorectal cancer cells and improves radiosensitivity by blocking repair of radiation-induced DNA double-strand breaks.
    Khozooei S; Veerappan S; Bonzheim I; Singer S; Gani C; Toulany M
    Radiother Oncol; 2023 Nov; 188():109867. PubMed ID: 37634766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.
    Song H; Hedayati M; Hobbs RF; Shao C; Bruchertseifer F; Morgenstern A; Deweese TL; Sgouros G
    Mol Cancer Ther; 2013 Oct; 12(10):2043-54. PubMed ID: 23873849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
    Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
    Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer.
    Sriramulu S; Thoidingjam S; Chen WM; Hassan O; Siddiqui F; Brown SL; Movsas B; Green MD; Davis AJ; Speers C; Walker E; Nyati S
    J Exp Clin Cancer Res; 2024 Jun; 43(1):163. PubMed ID: 38863037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
    Dinkelborg PH; Wang M; Gheorghiu L; Gurski JM; Hong TS; Benes CH; Juric D; Jimenez RB; Borgmann K; Willers H
    Breast Cancer Res Treat; 2019 Apr; 174(3):605-613. PubMed ID: 30607635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.
    Chitnis MM; Lodhia KA; Aleksic T; Gao S; Protheroe AS; Macaulay VM
    Oncogene; 2014 Nov; 33(45):5262-73. PubMed ID: 24186206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer.
    Su YH; Wu YZ; Ann DK; Chen JL; Kuo CY
    Cell Death Dis; 2023 Jan; 14(1):53. PubMed ID: 36681663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.
    Toulany M; Schickfluss TA; Eicheler W; Kehlbach R; Schittek B; Rodemann HP
    Breast Cancer Res; 2011 Mar; 13(2):R28. PubMed ID: 21392397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.
    Toulany M
    Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30621219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
    Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
    Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophilic fatty acids impair RAD51 function and potentiate the effects of DNA-damaging agents on growth of triple-negative breast cells.
    Asan A; Skoko JJ; Woodcock CC; Wingert BM; Woodcock SR; Normolle D; Huang Y; Stark JM; Camacho CJ; Freeman BA; Neumann CA
    J Biol Chem; 2019 Jan; 294(2):397-404. PubMed ID: 30478172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.
    Estrada-Bernal A; Chatterjee M; Haque SJ; Yang L; Morgan MA; Kotian S; Morrell D; Chakravarti A; Williams TM
    Cell Cycle; 2015; 14(23):3713-24. PubMed ID: 26505547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
    Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
    Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
    Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
    Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
    Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
    Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CD44high Subpopulation of Multifraction Irradiation-Surviving NSCLC Cells Exhibits Partial EMT-Program Activation and DNA Damage Response Depending on Their p53 Status.
    Pustovalova M; Alhaddad L; Blokhina T; Smetanina N; Chigasova A; Chuprov-Netochin R; Eremin P; Gilmutdinova I; Osipov AN; Leonov S
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNA double strand break repair with hyperthermia and DNA-PKcs inhibition to enhance the effect of radiation treatment.
    van Oorschot B; Granata G; Di Franco S; Ten Cate R; Rodermond HM; Todaro M; Medema JP; Franken NA
    Oncotarget; 2016 Oct; 7(40):65504-65513. PubMed ID: 27602767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.